Subclinical primary aldosteronism.
Journal
Archives of endocrinology and metabolism
Journal Volume
70
Journal Issue
Spec 1
Start Page
e250400
End Page
e250400
ISSN
2359-4292
Date Issued
2025-11-28
Author(s)
Abstract
Primary aldosteronism (PA) is a major contributor to hypertension and cardiovascular disease. Subclinical PA, a preclinical or early manifestation of PA, has been identified in individuals with normal blood pressure and in those with mild hypertension without signs or symptoms of overt PA, using evidence from histopathology, hormonal biochemistry, proteomic, and genetic studies. Longitudinal studies have shown that subclinical PA increases the risk for developing incident hypertension, adverse cardiovascular remodeling, major adverse cardiovascular events, and chronic kidney disease. Given the clinical relevance of subclinical PA on the pathogenesis of cardiorenal disease, future studies should focus on methods to enhance early detection and assessment of the impact of early aldosterone-directed interventions for preventing adverse clinical outcomes.
Subjects
Aldosterone
adrenal
primary aldosteronism
renin
subclinical primary aldosteronism
Type
review article